Meeting
2022 ASCO Genitourinary Cancers Symposium
Expanding the use of targeted therapy for urothelial bladder cancer (UBC): Non-FGFR3 receptor tyrosine kinase (RTK) gene rearrangements (ReAr) and fusions (fus).
Authors
Andrea Necchi
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy
Andrea Necchi , Dean C. Pavlick , Gennady Bratslavsky , Joseph M Jacob , Oleksandr Kravtsov , Philippe E. Spiess , Petros Grivas , Vamsi Parini , Brennan Decker , Douglas I. Lin , Natalie Danziger , Mia Alyce Levy , Jeffrey S. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 550)
DOI
10.1200/JCO.2022.40.6_suppl.550
Abstract #
550
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
First Author: Milind M. Javle
Poster
2018 ASCO Annual Meeting
Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).
First Author: Ben C. Creelan
Poster
2023 ASCO Annual Meeting
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).
First Author: John Leonard Fox
Poster
2022 ASCO Annual Meeting
Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC).
First Author: Maroun Bou Zerdan